NJ A5921

Drug manufacturers and wholesale distributors would be exempt from pharmacist licensing requirements when distributing dialysate drugs and devices for home dialysis to patients with end-stage renal disease

Exemption requires that dialysate drugs and devices be FDA-approved, held in original sealed packaging, and delivered only upon receipt of a physician's order

Delivery must be made directly to the patient or patient's designee for self-administration, or to a health care provider or institution for administration

Manufacturers must contract with a board-registered consultant pharmacist to provide weekly quality assurance assessments of home dialysis drug storage and distribution

The bill would take effect on the first day of the third month following enactment